Official ESCRS | European Society of Cataract & Refractive Surgeons


Early visual recovery comparison after combined phaco–iStent inject, phaco–non-penetrating deep sclerectomy, phaco–XEN implant and phaco–ExPress implant: a pilot study

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Combined Cataract Surgery & Cataract Surgery Complications

Venue: Poster Village: Pod 1

First Author: : J.Sanchez-Pina SPAIN

Co Author(s): :    C. Sanchez   B. Blanco Torcal   B. Puerto Hernandez   C. Lopez Caballero              

Abstract Details


To evaluate the early visual outcomes of combined cataract surgery and glaucoma surgery, either with the implantation of a shut device as iStent® trabecular micro-bypass device, Xen implant or Express shunt device, or performing a non-penetrating deep sclerectomy (NPDS).


Clínica Rementería, Madrid. Spain.


63 eyes that undergo combined cataract and glaucoma were evaluated. There were 15 eyes in the phaco-XEN implant group, 16 in the phaco-ExPress, 22 in the phaco-NPDS and 10 in the phaco-iStent group. All groups were matched by glaucoma severity and number of ocular hypotensive drugs. Visual Acuity (VA), best corrected visual acuity (BCVA), and refraction were assessed on days 1 and 7, and 1 month.


First day VA were 0.54 ± 0.18 in XEN group,  0.33 ±0.21 in EX-PRESS group, 0.54 ±0.26 in NPDS and 0.55 ± 0.41 mmHg in iStent group (p = 0.07). At 7 days 0.81 ± 0.19, 0.47 ± 0.21, 0.60 ±0.23 and 0.79 ± 0.32 in the XEN, P-ExPress, NPDS and iStent Group, respectively (p=0.0007). 1 month mean VA were 0.76 ± 0.25 in XEN, 0.57 ±0.29 in  EX-PRESS, 0.67 ±0.28 in NPDS and 0.72 ± 0.33 mmHg in iStent group (p =0.3) while BCVA were 0.92+0.10(XEN group), 0.83 +0.39 (iStent group),  0.83+0.34 (ExPress group) and 0.66+0.21 (NDPS group) (p=0.04)


In our study group, combined cataract and glaucoma surgery, with all those different techniques, are comparable procedures in visual acuity recovery during the first month follow-up, even further studies are needed to validate our results.

Financial Disclosure:


Back to previous